Literature DB >> 18072127

Pattern of dipyrone exposure in Texas, 1998 to 2004.

Mathias B Forrester1.   

Abstract

INTRODUCTION: Dipyrone is an analgesic and antipyretic agent. The purpose of this study was to describe the pattern of dipyrone exposures reported to poison centers.
METHODS: Human dipyrone exposures reported to 6 Texas poison centers from 1998 to 2004 were identified. Isolated and non-isolated cases were compared with respect to various factors.
RESULTS: When compared to the Census, dipyrone exposures were significantly more likely to have been reported from regions closer to the Mexican border (53% vs 9%). Of 81 dipyrone exposures, 52 (64%) were isolated and 29 (36%) were non-isolated. Most of the dipyrone exposures occurred at the patient's own residence (72/76 or 95%) and the patients were more likely to be female (54/81 or 67%). Although the majority of both types of dipyrone exposures were adults (47/78 or 60%), children, less than 6 years of age, accounted for a higher proportion of isolated exposures (33% vs 10%) while a higher proportion of non-isolated exposures involved older children (28% vs 8%). Twenty-two percent (11/51) of isolated cases were intentional while 59% (17/29) of non-isolated cases were intentional. Of those cases with a known medical outcome, the medical outcome was no adverse clinical effect for 76% (16/21) of isolated exposures and 42% (8/19) of non-isolated exposures. The specific adverse clinical effects reported for isolated exposures were primarily neurological (n = 6), gastrointestinal (n = 4), and dermal (n = 3). The most frequently reported treatment for isolated exposures was some form of decontamination (n = 11).
CONCLUSIONS: Isolated and non-isolated dipyrone exposures varied with respect to patient age, exposure reason, management site, medical outcome.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 18072127      PMCID: PMC3550155          DOI: 10.1007/bf03161018

Source DB:  PubMed          Journal:  J Med Toxicol        ISSN: 1556-9039


  9 in total

1.  Mexican border medications: potential toxicity.

Authors:  A M Lugo
Journal:  J Toxicol Clin Toxicol       Date:  1999

2.  Rates of cutaneous reactions to drugs. A report from the Boston Collaborative Drug Surveillance Program.

Authors:  K A Arndt; H Jick
Journal:  JAMA       Date:  1976-03-01       Impact factor: 56.272

Review 3.  Allergic reactions to drugs and biologic agents.

Authors:  J A Anderson; N F Adkinson
Journal:  JAMA       Date:  1987-11-27       Impact factor: 56.272

4.  Use of Neo-melubrina, a banned antipyretic drug, in San Diego, California: a survey of patients and providers.

Authors:  L Taylor; S Abarca; B Henry; L Friedman
Journal:  West J Med       Date:  2001-09

5.  Cyclooxygenase and lipoxygenase metabolite synthesis by polymorphonuclear neutrophils: in vitro effect of dipyrone.

Authors:  R Abbate; A M Gori; S Pinto; M Attanasio; R Paniccia; M Coppo; S Castellani; B Giusti; M Boddi; G G Neri Serneri
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  1990-10       Impact factor: 4.006

6.  Metamizole use by Latino immigrants: a common and potentially harmful home remedy.

Authors:  Joshua L Bonkowsky; J Kimble Frazer; Karen F Buchi; Carrie L Byington
Journal:  Pediatrics       Date:  2002-06       Impact factor: 7.124

7.  Activity of dipyrone on intraplatelet arachidonic acid metabolism: an in vitro study.

Authors:  R Abbate; S Pinto; A M Gori; R Paniccia; M Coppo; G G Neri Serneri
Journal:  Pharmacol Res       Date:  1989 Jan-Feb       Impact factor: 7.658

8.  The effects of metamizol on prostaglandin synthesis in man.

Authors:  J C Frölich; W A Rupp; R M Zapf; M J Badian
Journal:  Agents Actions Suppl       Date:  1986

9.  Dipyrone overdose.

Authors:  Yedidia Bentur; Omri Cohen
Journal:  J Toxicol Clin Toxicol       Date:  2004
  9 in total
  1 in total

1.  Metamizole: An underrated agent causing severe idiosyncratic drug-induced liver injury.

Authors:  Marcial Sebode; Martin Reike-Kunze; Sören Weidemann; Roman Zenouzi; Johannes Hartl; Moritz Peiseler; Timur Liwinski; Lisa Schulz; Christina Weiler-Normann; Martina Sterneck; Ansgar W Lohse; Christoph Schramm
Journal:  Br J Clin Pharmacol       Date:  2020-03-03       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.